21.20
price down icon3.42%   -0.75
after-market After Hours: 21.20
loading
Enliven Therapeutics Inc stock is traded at $21.20, with a volume of 183.61K. It is down -3.42% in the last 24 hours and down -1.40% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$21.95
Open:
$21.87
24h Volume:
183.61K
Relative Volume:
0.38
Market Cap:
$1.04B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-11.22
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-6.44%
1M Performance:
-1.40%
6M Performance:
-3.02%
1Y Performance:
-15.27%
1-Day Range:
Value
$21.04
$22.45
1-Week Range:
Value
$21.04
$23.41
52-Week Range:
Value
$13.30
$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
Name
Enliven Therapeutics Inc
Name
Phone
720-647-8519
Name
Address
6200 LOOKOUT ROAD, BOULDER
Name
Employee
65
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ELVN
Enliven Therapeutics Inc
21.20 1.32B 0 -85.21M -68.53M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-16-25 Initiated Goldman Buy
Dec-13-24 Initiated BTIG Research Buy
Sep-09-24 Initiated H.C. Wainwright Buy
Jun-11-24 Initiated Robert W. Baird Outperform
Apr-09-24 Initiated Mizuho Buy
Mar-29-23 Initiated Jefferies Buy
View All

Enliven Therapeutics Inc Stock (ELVN) Latest News

pulisher
02:43 AM

Will Enliven Therapeutics Inc. stock split in the near futureMoney Making Low Risk Plans - Newser

02:43 AM
pulisher
01:59 AM

What risks could impact Enliven Therapeutics Inc. stock performanceFree Stock Index Interpretation - jammulinksnews.com

01:59 AM
pulisher
Jul 24, 2025

What drives Enliven Therapeutics Inc. stock priceSky-high profits - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Polis encourages life-sciences companies to move to Colorado - BizWest

Jul 24, 2025
pulisher
Jul 23, 2025

Enliven Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Enliven Therapeutics Inc. stockOutstanding investment returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Enliven Therapeutics Inc. a good long term investmentTriple-digit growth rates - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Enliven Therapeutics CSO sells $278k in shares - Investing.com Australia

Jul 23, 2025
pulisher
Jul 23, 2025

Enliven Therapeutics CSO sells $278k in shares By Investing.com - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN

Jul 23, 2025
pulisher
Jul 23, 2025

Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

Why Enliven Therapeutics Inc. stock attracts strong analyst attentionDaily Price Surge List - Newser

Jul 22, 2025
pulisher
Jul 20, 2025

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN

Jul 20, 2025
pulisher
Jul 19, 2025

Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - The Globe and Mail

Jul 19, 2025
pulisher
Jul 19, 2025

Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail

Jul 19, 2025
pulisher
Jul 17, 2025

Enliven Therapeutics’ Promising CML Treatment: A Study Update - TipRanks

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Enliven Therapeutics Inc. stock price move sharplyFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Enliven Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

(ELVN) Proactive Strategies - news.stocktradersdaily.com

Jul 15, 2025
pulisher
Jul 15, 2025

Enliven Therapeutics CFO Hohl sells $22,655 in shares - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $41.20 - Defense World

Jul 14, 2025
pulisher
Jul 10, 2025

Enliven Therapeutics Breaks Above 200-Day Moving AverageBullish for ELVN - Nasdaq

Jul 10, 2025
pulisher
Jul 09, 2025

Enliven Therapeutics COO Patel sells shares worth $131950 By Investing.com - Investing.com Canada

Jul 09, 2025

Enliven Therapeutics Inc Stock (ELVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Enliven Therapeutics Inc Stock (ELVN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kintz Samuel
PRESIDENT AND CEO
Jul 17 '25
Sale
22.52
12,500
281,518
940,392
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):